Patients’ baseline demographic and clinical characteristics did not differ between the rotigotine and placebo groups in terms of age; educational level; time since diagnosis of Alzheimer disease; time since current cholinesterase inhibitor treatment initiated; being an APOE ε4 carrier; and MMSE, ADAS-Cog-11, FAB, ADCS-ADL, and NPI scores (Table 1). The gene discussed is APOE; the disease is Alzheimer disease.